✨ Free AI Report
Talphera, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Talphera, Inc.
Research Preview

Talphera, Inc.: Business Overview, Financials & Competitive Analysis

Talphera is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate, Niyad, is a lyophilized formulation of...

Analyst-debate audio for Talphera, Inc.

AskCyborg analysts argue the bull and bear cases for Talphera, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Talphera, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Clinical-stage pharmaceutical with niche market focus, dependent on Niyad regulatory approval success in specialized medical...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals / Biotech
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Talphera, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Talphera, Inc. Overview

Pro stress-test →

Talphera is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate, Niyad, is a lyophilized formulation of nafamostat being studied as an anticoagulant for the extracorporeal circuit. The company is progressing clinical trials with potential market applications in dialysis and critical care.

Strategic Profile

Pro stress-test →

The company is also developing LTX-608, a nafamostat formulation for direct IV infusion for indications including antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as pre-filled syringe product candidates. The FDA approved reducing the NEPHRO CRRT clinical study from 166 to 70 patients with 90% power, and the company activated clinical study sites targeting completion by year-end 2025.

Competitive Landscape

Pro stress-test →

Talphera competes in specialized anticoagulation and critical care therapeutics space. Competitors include larger pharma companies with established dialysis solutions and emerging biotech firms developing nafamostat formulations. The company's niche focus on medically supervised settings with specialized delivery mechanisms differentiates it, though it faces competition from established anticoagulation providers and broader ARDS/critical care treatment developers.

Industry Context

Talphera, Inc. operates in Specialty Pharmaceuticals / Biotech.

Key facts

Founded: 2005 · Headquarters: San Mateo, California · Market cap: $51.5M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Talphera, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Talphera, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ApixabanDirect oral anticoagulant for various indications→Heparin-based anticoagulantsStandard anticoagulation for CRRT and extracorporeal circuits→RemdesivirAntiviral for severe respiratory infections→

Compare Talphera, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Talphera, Inc. operates in Specialty Pharmaceuticals / Biotech. See how the rest of the sector scores on the Cyborg framework.

Top companies in Specialty Pharmaceuticals by Cyborg Score

Browse Specialty Pharmaceuticals / Biotech research →
NEW · MCP server

Ask your AI assistant about Talphera, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Talphera, Inc. and its top competitor on Cyborg Score”
“What did Talphera, Inc. do this quarter?”
“Is Talphera, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Talphera, Inc. do?+
Talphera is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate, Niyad, is a lyophilized formulation of...
What is Talphera, Inc.'s Cyborg Score?+
Talphera, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Talphera, Inc.'s main competitors?+
Named competitors include Apixaban, Heparin-based anticoagulants, Remdesivir. The full competitive landscape is in the AskCyborg report.
How can I get the full Talphera, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Talphera, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Talphera, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Catalyst Pharmaceuticals, Inc.7Achieve Life Sciences, Inc.7Assertio Holdings, Inc.7Viatris Inc.7Xeris Biopharma Holdings, Inc.6Allergy Therapeutics PLC6Eagle Pharmaceuticals Inc.6Santhera Pharmaceuticals Holding AG6Supernus Pharmaceuticals, Inc.5Amphastar Pharmaceuticals, Inc.Top companies in Specialty Pharmaceuticals by Cyborg Score